Complete Filing Data
BriaCell Therapeutics Corp. reported General And Administrative Expense of $5.93 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean BriaCell Therapeutics Corp. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income * | -$26.3M | -$4.8M | -$20.3M | -$26.8M | -$13.8M |
| General And Administrative Expense | $5.9M | $6.2M | $7.9M | $7.3M | $5.0M |
| Research And Development Expense | $21.3M | $27.2M | $15.3M | $8.0M | $2.0M |
| Operating Income Loss | -$27.2M | -$33.3M | -$23.3M | -$15.3M | -$7.0M |
| Nonoperating Income Expense | $114.5K | $262.6K | $850.3K | -$11.5M | |
| Operating Expenses | $27.2M | $33.3M | $23.3M | ||
| Net Income Loss Attributable To Noncontrolling Interest | -$244.3K | -$140.1K | |||
| Interest Expense | $979.00 | $78.6K | |||
| Income Loss From Equity Method Investments | -$224.2K | -$106.5K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$8.2M | -$6.1M | -$6.3M | -$5.8M | $1.7M | -$11.3M | $6.0M | -$4.9M | -$11.9M | -$1.1M | -$10.0M | $11.2M | -$27.5M |
| General And Administrative Expense | $1.6M | $1.5M | $1.5M | $1.5M | $1.6M | $1.6M | $1.6M | $1.8M | $1.4M | $2.1M | $1.9M | $1.9M | $1.4M |
| Research And Development Expense | $6.7M | $4.8M | $5.7M | $3.7M | $7.7M | $8.3M | $6.9M | $3.9M | $3.1M | $3.3M | $2.3M | $1.7M | $875.6K |
| Operating Income Loss | -$8.3M | -$6.3M | -$7.2M | -$5.2M | -$9.2M | -$9.8M | -$8.5M | -$5.7M | -$4.5M | -$5.4M | -$4.1M | -$3.6M | -$2.3M |
| Nonoperating Income Expense | $158.6K | -$9.8K | $67.4K | $11.7K | $13.2K | $81.6K | $179.8K | $781.6K | -$7.4M | $4.3M | -$5.9M | $14.8M | -$25.2M |
| Operating Expenses | $8.3M | $6.3M | $7.2M | $5.2M | $9.2M | $9.8M | $8.5M | $5.7M | $4.5M | $5.4M | $4.1M | $3.6M | $2.3M |
| Net Income Loss Attributable To Noncontrolling Interest | -$80.8K | -$98.0K | -$46.4K | -$27.1K | -$23.5K | -$39.3K | -$42.7K | ||||||
| Interest Expense | $979.00 | ||||||||||||
| Income Loss From Equity Method Investments | -$44.8K | -$62.7K | -$42.6K | -$71.5K | -$37.0K | -$18.3K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Stockholders Equity * | -$3.8M | $10.3M | $27.7M | -$2.7M | |
| Assets | $5.9M | $27.2M | $42.6M | $58.0M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $21.3M | $41.0M | |||
| Retained Earnings Accumulated Deficit | -$85.4M | -$80.7M | -$60.3M | -$29.1M | |
| Liabilities Noncurrent | $1.1M | $29.1M | $31.3M | $29.8M | |
| Liabilities Current | $7.5M | $1.8M | $941.1K | $556.8K | |
| Liabilities And Stockholders Equity | $5.9M | $27.2M | $42.6M | $58.0M | |
| Common Stock Value | $72.2M | $69.6M | $65.6M | $54.8M | |
| Cash And Cash Equivalents At Carrying Value | $862.1K | $21.3M | $41.0M | $57.3M | |
| Assets Noncurrent | $2.2M | $215.1K | $230.3K | $245.6K | |
| Assets Current | $3.7M | $26.9M | $42.3M | $57.8M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$138.7K | -$138.7K | -$138.7K | -$138.7K | |
| Accounts Payable Trade Current | $7.2M | $1.1M | $463.3K | $214.1K | |
| Accounts Payable And Other Accrued Liabilities Current | $290.4K | $677.7K | $477.8K | $342.7K | |
| Equity | -$3.8M | $10.3M | $27.7M | -$2.7M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $57.3M | $21.2K | |||
| Equity Method Investments | $2.00 | $2.00 | $2.00 | ||
| Finite Lived Intangible Assets Net | $230.3K | $245.6K | |||
| Common Stock No Par Value | $0.00 | $0.00 | |||
| Accounts Receivable Net Current | $24.1K | $12.6K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $9.4M | $17.3M | $11.9M | $3.2M | $3.7M | -$2.7M | -$6.2M | -$8.3M | $2.5M | -$5.9M | -$1.3M | $10.3M | $10.0M | $16.4M | $1.6M | ||
| Assets | $13.1M | $21.6M | $17.0M | $9.4M | $10.4M | $6.2M | $12.2M | $18.6M | $29.7M | $34.2M | $38.5M | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $2.7M | $10.5M | $12.5M | $5.0M | $5.8M | $862.1K | $935.7K | $6.2M | $13.6M | $28.2M | $33.5M | ||||||
| Retained Earnings Accumulated Deficit | -$120.0M | -$111.8M | -$103.7M | -$97.5M | -$91.2M | -$84.2M | -$85.9M | -$74.7M | -$78.2M | -$73.3M | -$61.5M | ||||||
| Liabilities Noncurrent | $406.9K | $337.7K | $730.0K | $905.8K | $1.7M | $5.7M | $16.6M | $15.1M | $34.2M | $34.8M | $27.1M | ||||||
| Liabilities Current | $3.3M | $4.0M | $4.3M | $5.2M | $5.0M | $6.8M | $3.9M | $1.0M | $1.4M | $670.4K | $974.1K | ||||||
| Liabilities And Stockholders Equity | $13.1M | $21.6M | $17.0M | $9.4M | $10.4M | $6.2M | $12.2M | $18.6M | $29.7M | $34.2M | $38.5M | ||||||
| Common Stock Value | $101.7M | $101.7M | $94.0M | $85.5M | $82.0M | $69.6M | $69.6M | $69.6M | $65.6M | $65.6M | $65.6M | ||||||
| Cash And Cash Equivalents At Carrying Value | $2.7M | $10.5M | $12.5M | $5.0M | $5.8M | $935.7K | $6.2M | $13.6M | $28.2M | $33.5M | $37.5M | ||||||
| Assets Noncurrent | $1.7M | $1.7M | $2.2M | $2.2M | $2.2M | $673.3K | $489.1K | $211.3K | $218.9K | $222.7K | $226.5K | ||||||
| Assets Current | $11.3M | $19.9M | $14.8M | $7.2M | $8.2M | $5.5M | $11.7M | $18.4M | $29.5M | $33.9M | $38.2M | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$138.7K | -$138.7K | -$138.7K | -$138.7K | -$138.7K | -$138.7K | -$138.7K | -$138.7K | -$138.7K | -$138.7K | -$138.7K | ||||||
| Accounts Payable Trade Current | $2.1M | $3.3M | $3.3M | $5.0M | $4.2M | $6.4M | $3.7M | $433.9K | $995.3K | $582.5K | $791.7K | ||||||
| Accounts Payable And Other Accrued Liabilities Current | $1.2M | $694.3K | $1.1M | $227.6K | $754.7K | $335.4K | $212.9K | $612.6K | $387.8K | $88.0K | $182.3K | ||||||
| Equity | $9.4M | $17.3M | $11.9M | $3.2M | $3.7M | -$2.7M | -$6.2M | -$8.3M | $2.5M | -$5.9M | -$1.3M | $10.3M | $10.0M | $16.4M | $1.6M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $13.6M | $21.3M | $28.2M | $33.5M | $37.5M | $41.0M | $44.5M | $48.0M | $55.5M | ||||||||
| Equity Method Investments | $2.00 | $2.00 | $2.00 | $2.00 | $2.00 | $2.00 | |||||||||||
| Finite Lived Intangible Assets Net | $203.6K | $207.4K | $211.3K | $215.1K | $218.9K | $222.7K | $226.5K | ||||||||||
| Common Stock No Par Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||
| Accounts Receivable Net Current | $15.2K | $30.1K | $21.4K | $18.9K | $14.9K | $8.9K | $29.7K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $1.1M | $1.8M | $2.2M | $3.1M | $2.0M |
| Share Based Compensation | $776.9K | $1.8M | $2.2M | $3.1M | $2.0M |
| Net Cash Provided By Used In Operating Activities | -$28.2M | -$24.1M | -$23.7M | -$12.5M | -$7.8M |
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | $753.9K | -$387.3K | $199.9K | $135.1K | -$785.4K |
| Increase Decrease In Prepaid Expense | -$492.3K | -$2.1M | $4.4M | $764.1K | $101.0K |
| Increase Decrease In Accounts Receivable | -$733.6K | $732.6K | -$5.2K | $11.5K | -$9.9K |
| Increase Decrease In Accounts Payable | -$3.9M | $6.0M | $660.5K | $249.2K | -$1.4M |
| Net Cash Provided By Used In Financing Activities | $45.4M | $4.4M | $4.0M | -$3.7M | $65.0M |
| Net Cash Provided By Used In Investing Activities | -$7.6M | -$681.8K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $294.7K | $224.8K | $635.1K | $267.0K | $392.2K | $500.2K | $533.8K | $281.2K | $266.8K | $1.1M | $863.6K | $814.9K | $518.1K |
| Share Based Compensation | $294.7K | $224.8K | $285.1K | $267.0K | $392.2K | $500.2K | $533.8K | $281.2K | $266.8K | $1.1M | $863.6K | $814.9K | $518.1K |
| Net Cash Provided By Used In Operating Activities | -$7.7M | -$7.0M | -$7.6M | -$3.5M | -$1.8M | ||||||||
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | $494.6K | $464.3K | -$65.1K | -$295.5K | -$154.8K | ||||||||
| Increase Decrease In Prepaid Expense | $371.9K | -$937.8K | -$538.8K | -$110.1K | |||||||||
| Increase Decrease In Accounts Receivable | -$736.8K | $2.5K | $5.6K | $6.8K | |||||||||
| Increase Decrease In Accounts Payable | -$1.2M | -$2.9M | -$689.8K | $328.5K | $29.3K | ||||||||
| Net Cash Provided By Used In Financing Activities | $12.0M | -$47.3K | |||||||||||
| Net Cash Provided By Used In Investing Activities | -$75.0K | -$75.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 423.1K | 109.7K | 15.6M | 15.5M | 4.5M |
| Weighted Average Number Of Diluted Shares Outstanding | 423.1K | 109.7K | 15.6M | 15.5M | |
| Earnings Per Share Diluted | $-62.19 | $-43.68 | $-1.30 | $-1.73 | |
| Earnings Per Share Basic | $-62.19 | $-43.68 | $-1.30 | $-1.73 | $-3.06 |
| Common Stock Shares Outstanding | 121.9K | 16.0M | 15.5M | 15.3M | |
| Common Stock Shares Issued | 121.9K | 16.0M | 15.5M | 15.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 1.9M | 3.7M | 2.7M | 177.6K | 1.1M | 1.1M | 16.0M | 15.5M | 15.5M | 15.5M | 15.4M | 15.8M | 15.2M | |
| Weighted Average Number Of Diluted Shares Outstanding | 1.9M | 3.7M | 2.7M | 177.6K | 1.1M | 1.1M | 16.7M | 15.5M | 15.5M | 15.5M | 15.4M | 18.4M | ||
| Earnings Per Share Diluted | $-4.35 | $-1.64 | $-2.33 | $-32.67 | $1.61 | $-10.64 | $-0.50 | $-0.32 | $-0.77 | $-0.07 | $-0.65 | $0.04 | ||
| Earnings Per Share Basic | $-4.35 | $-1.64 | $-2.33 | $-32.67 | $1.61 | $-10.64 | $0.38 | $-0.32 | $-0.77 | $-0.07 | $0.71 | $-1.81 | ||
| Common Stock Shares Outstanding | 1.9M | 6.6M | 294.7K | 36.2M | 16.0M | 16.0M | 16.0M | 15.5M | 15.5M | 15.5M | ||||
| Common Stock Shares Issued | 1.9M | 6.6M | 36.2M | 16.0M | 16.0M | 16.0M | 15.5M | 15.5M | 15.5M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Fair Value Adjustment Of Warrants | -$758.4K | -$28.2M | -$2.1M | $11.7M | $4.4M |
| Warrant Reserve | $1.8M | ||||
| Stock Issued During Period Value New Issues | $44.6M | $4.4M | $4.0M | $12.4M | |
| Sharebased Payment Reserve | $9.2M | $7.4M | |||
| Prepaid Expense Current | $1.3M | $516.9K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fair Value Adjustment Of Warrants | $69.2K | -$175.8K | -$806.8K | $616.6K | -$10.9M | $1.6M | -$14.3M | -$539.4K | $7.6M | -$4.1M | $5.9M | -$14.8M | $25.3M | |||
| Warrant Reserve | $17.7M | $17.7M | $11.9M | $5.7M | $3.9M | |||||||||||
| Stock Issued During Period Value New Issues | $14.7M | $3.1M | $5.6M | $8.5M | ||||||||||||
| Sharebased Payment Reserve | $10.6M | $10.3M | $10.3M | $10.1M | $9.5M | $8.8M | $8.4M | |||||||||
| Prepaid Expense Current | $4.6M | $5.5M | $4.7M | $5.7M | $1.3M | $429.4K | $742.1K |
Most recent annual filing with the SEC: October 16, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.